BML Investment Partners, L.P. 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-27 7:26 pm Sale | 2026-04-23 | 13G | ACLARIS THERAPEUTICS INC ACRS | BML Investment Partners, L.P. | 13,950,000 9.900% | -300,000 (-2.11%) | Filing |
| 2026-02-09 1:42 pm Unchanged | 2025-12-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | BML Investment Partners, L.P. | 14,250,000 11.900% | 0 (Unchanged) | Filing |
| 2025-02-13 2:26 pm Purchase | 2024-12-31 | 13G | ACLARIS THERAPEUTICS INC ACRS | BML Investment Partners, L.P. | 14,250,000 13.300% | 4,854,066 (+51.66%) | Filing |
| 2024-02-08 11:14 am Purchase | 2024-02-07 | 13G | ACLARIS THERAPEUTICS INC ACRS | BML Investment Partners, L.P. | 9,395,934 13.300% | 4,895,934 (+108.80%) | Filing |
| 2024-01-16 5:24 pm Purchase | 2024-01-11 | 13G | ACLARIS THERAPEUTICS INC ACRS | BML Investment Partners, L.P. | 4,500,000 6.400% | 4,500,000 (New Position) | Filing |